16/06/22 -"Our target price is cut on account of a drop in both intrinsic valuations (DCF and NAV) as well as the relative valuations, which now factor in the multiple near-term headwinds (supply chain ..."
Pages
57
Language
English
Published on
16/06/22
You may also be interested by these reports :
28/06/22
Philips shared the results of tests conducted on a sample of sleep apnea devices from the US and Canada, wherein the majority of the devices passed ...
28/06/22
Following the availability of the formal annual report, we have integrated the audited FY21 actual figures which were consistent with the preliminary ...
21/06/22
We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) ...
21/06/22
With the double-whammy of waning pandemic-driven opportunities and the markets becoming increasingly-wary of high P/E MedTechs, testing stocks are ...